T 1095
Alternative Names: RWJ 394718Latest Information Update: 02 Jul 2007
At a glance
- Originator Tanabe Seiyaku
- Developer Johnson & Johnson; Tanabe Seiyaku
- Class Antihyperglycaemics; Glucosides
- Mechanism of Action Sodium-glucose transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 12 Jan 2004 Tanabe Seiyaku is switching development to a backup compound
- 25 Jun 2003 Data presented at the 63rd Scientific Sessions of the American Diabetes Association (ADA-2003) have been added to the Diabetes mellitus pharmacodynamics section
- 16 Oct 2002 Phase-II clinical trials in Diabetes mellitus in Europe (PO)